Today: 20 May 2026
Bitcoin price steadies near $90K after ETF outflows; Coinbase, Strategy shares mixed premarket

Bitcoin price steadies near $90K after ETF outflows; Coinbase, Strategy shares mixed premarket

NEW YORK, Jan 9, 2026, 06:30 (EST) — Premarket

  • Bitcoin rose 0.4% to about $90,462 after swinging below $90,000 overnight.
  • U.S. spot bitcoin ETFs logged roughly $885 million of net withdrawals over the last two sessions, data showed.
  • Crypto-linked stocks were mixed in premarket trade, with Strategy up and Coinbase little changed.

Bitcoin steadied near $90,000 on Friday, edging higher in early U.S. trade, while crypto-linked stocks split in the premarket. Coinbase Global dipped 0.1% and Strategy rose 3.2%, with miners Marathon Digital up 3.7% and Riot Platforms down about 1%.

The key near-term driver is still flows, not slogans. U.S. spot bitcoin ETFs — funds that hold bitcoin and trade like stocks — saw net outflows of $486.1 million on Jan. 7 and $398.8 million on Jan. 8, led by BlackRock’s IBIT and Fidelity’s FBTC, Farside Investors data showed.

Investors are also bracing for macro news that can jolt rate bets and the dollar, both of which tend to spill into crypto. Reuters polling shows economists expect U.S. payrolls to rise 60,000 in December and the unemployment rate to ease to 4.5%, while stock index futures were subdued ahead of the report and a Supreme Court tariff ruling.

Federal Reserve Governor Stephen Miran said on Thursday he was looking for about 150 basis points of rate cuts this year, arguing underlying inflation was running close to the Fed’s target. “I’m looking for about a point and a half of cuts,” Miran said in an interview. reuters.com

Strategy, which investors use as a liquid proxy for bitcoin exposure, has drawn extra attention after index provider MSCI shelved a plan to exclude some crypto-treasury firms from its indexes. The move “removes a material near-term technical risk” for a slice of bitcoin-proxy equities, Owen Lau, an analyst at Clear Street, wrote. reuters.com

But the setup is fragile. If the jobs data comes in hotter than expected, traders could push yields higher and lean into the dollar, a mix that often pressures assets that do not pay interest — including bitcoin — and can revive selling around the $90,000 level.

Stock Market Today

  • SpaceX IPO Filing Could Propel Elon Musk to Trillionaire Status
    May 20, 2026, 5:46 PM EDT. SpaceX's recent S-1 filing signals a potential initial public offering (IPO) that could surpass the 2020 record set by Saudi Aramco as the largest IPO in history. The deal is expected to significantly increase the valuation of SpaceX, potentially making CEO Elon Musk a trillionaire. This move highlights the growing investor interest in private spaceflight companies and the expanding market for space exploration-related ventures.

Latest articles

Xanadu Jumps 20% After Quantum Selloff, Filing Remains Over XNDU

Xanadu Jumps 20% After Quantum Selloff, Filing Remains Over XNDU

20 May 2026
Xanadu Quantum Technologies’ shares surged 20.4% to $14.13 Wednesday, rebounding after a sharp May decline. The company reported Q1 revenue of $2.83 million and a net loss of $20.6 million, with 43.3 million Class B shares outstanding and a prospectus covering up to 293.7 million more. Other quantum stocks also rose. Xanadu is in talks for up to $285 million in Canadian government support.
MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

20 May 2026
MicroAlgo shares surged 39.95% to $5.36 after the company announced a quantum image-processing algorithm, with volume reaching 9.74 million shares versus a 447,270 average. The stock hit $6.87 intraday before slipping to $5.22 after hours. No customer deals, revenue targets, or product launch dates were disclosed. Market cap stood near $66.7 million at the close.
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

20 May 2026
Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
Ondas stock jumps again in premarket after SEC resale filing, with insider sale notice in the mix
Previous Story

Ondas stock jumps again in premarket after SEC resale filing, with insider sale notice in the mix

Nvidia stock slips before the bell as China H200 payment terms jolt AI stocks
Next Story

Nvidia stock slips before the bell as China H200 payment terms jolt AI stocks

Go toTop